Active

Psoriatic Arthritis

Active

Ankylosing Spondylitis

Moderate to Severe

Juvenile Idiopathic Arthritis

Non-Infectious

Intermediate, Posterior and Panuveitis

Active

Psoriatic Arthritis

Moderate to Severe

Hidradenitis Suppurativa

Gastroenterology

Moderate to Severe

Crohn's Disease

Moderate to Severe

Pediatric Crohn's Disease

Moderate to Severe

Ulcerative Colitis

Ophthalmology

Non-Infectious

Intermediate, Posterior and Panuveitis

For moderate to severe rheumatoid arthritis (RA) in adult MTX‑IR patients1

Older woman in a harness, ziplining
The first approved RA therapy to demonstrate superiority in a head-to-head trial vs HUMIRA (adalimumab) + MTX The first approved RA therapy to demonstrate superiority in a head-to-head trial vs HUMIRA (adalimumab) + MTX The first approved RA therapy to demonstrate superiority in a head-to-head trial vs HUMIRA (adalimumab) + MTX

SELECT-COMPARE
(JAK inhibitor vs TNF inhibitor)

A study in MTX-IR patients:

  • RINVOQ + MTX vs HUMIRA® (adalimumab) + MTX

RINVOQ + MTX achieved superiority in its ranked secondary endpoints at Week 12 vs HUMIRA® (adalimumab) + MTX:

ACR50, HAQ-DI, and Pain Reduction

SELECT-CHOICE
(JAK inhibitor vs T-cell inhibitor)

A study in bDMARD-IR patients:

  • RINVOQ + csDMARDs vs ORENCIA® (abatacept) + csDMARDs

RINVOQ + csDMARDs achieved superiority in its ranked secondary endpoint at Week 12 vs ORENCIA® (abatacept) + csDMARDs:

DAS28-CRP<2.6

ACR=American College of Rheumatology; CRP=C-reactive protein; csDMARDs=conventional synthetic disease modifying anti‑rheumatic drugs; DAS28=disease activity score 28 joints; HAQ-DI=health assessment questionnaire disability index; IR=intolerance or inadequate response; JAK=janus kinase; MTX=methotrexate; TNF=tumor necrosis factor

Clinical Trial Overview

SELECT-COMPARE: Primary endpoint was ACR20 response at Week 12 MTX-IR

*P≤0.001 vs RINVOQ vs Placebo or MTX

SELECT‑COMPARE (Study RA-IV) Study Design Intro:1,2 
48‑week, randomized, double‑blind, active comparator‑controlled study of 1629 adult patients with moderate to severe RA who had an inadequate response to MTX. Patients on background MTX were randomized to receive RINVOQ 15 mg once daily (n=651), placebo (n=651), or adalimumab 40 mg EOW (n=327). The primary endpoint was ACR20 response at Week 12 vs Placebo.

SELECT-COMPARE: Primary endpoint was ACR20 response at Week 12 MTX-IR

P<0.001 vs ORENCIA® (abatacept); Treatment difference for change in DAS28‑CRP from baseline was -0.52 (-0.69, -0.35).

SELECT‑CHOICE Study Design Intro:3,4 
24-week, double-blind, active comparator–controlled study of 612 adult patients with moderate to severe RA who had an inadequate response or intolerance to bDMARDs. Patients on stable csDMARDs were randomized to receive RINVOQ 15 mg once daily (n=303) or weight‑based abatacept IV at 0, 2, and 4 weeks, and every 4 weeks thereafter (n=309). The primary endpoint was ΔDAS28‑CRP (noninferiority) at Week 12.

RINVOQ + MTX
vs a TNFi + MTX

Demonstrated superiority in ACR50 at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in ACR50 at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in ACR50 at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX

SELECT-COMPARE:
Superiority Data

A study in MTX‑IR patients

15
29
45*†
-0.3
-0.5
-0.6§
-16
-26
-32∣∣
SELECT-COMPARE: ACR50, HAQ-DI, and PAIN SELECT-COMPARE: ACR50, HAQ-DI, and PAIN SELECT-COMPARE: ACR50, HAQ-DI, and PAIN

P≤0.001 for RINVOQ + MTX vs Placebo + MTX; Analyses were not controlled for multiplicity; P‑values obtained through nominal statistical testing.

Signs and Symptoms, Physical Function & Pain Reduction

RINVOQ + MTX vs
HUMIRA (adalimumab) + MTX

SELECT-COMPARE:

DEMONSTRATED SUPERIORITY

IN ACR50 AT WEEK 122,5-10

A study in MTX‑IR patients

SELECT-COMPARE: ACR50 SELECT-COMPARE: ACR50 SELECT-COMPARE: ACR50
SELECT-COMPARE: Chart legend

Treatment groups are by initial randomization. Observations after rescue were handled using NRI (weeks 14-22) and LOCF (Week 26). For patients who discontinued at any time before or at Week 72, NRI was used.

P≤0.001 for RINVOQ + MTX vs Placebo + MTX; analysis was not controlled for multiplicity;
P-value obtained through nominal statistical testing.

Please see HUMIRA full Prescribing Information.

Please see HUMIRA full Prescribing Information.

SELECT-COMPARE:

DEMONSTRATED SUPERIORITY

in HAQ-DI AT WEEK 122,5-9,11

A study in MTX‑IR patients

SELECT-COMPARE: HAQ-DI SELECT-COMPARE: HAQ-DI SELECT-COMPARE: HAQ-DI
SELECT-COMPARE: Chart legend SELECT-COMPARE: Chart legend SELECT-COMPARE: Chart legend

Treatment groups are by initial randomization (ANCOVA). Observations after rescue treatment switch were imputed as LOCF.

Please see HUMIRA full Prescribing Information.

Please see HUMIRA full Prescribing Information.

SELECT-COMPARE:

DEMONSTRATED SUPERIORITY

in PAIN REDUCTION AT WEEK 122,5-9,12

In MTX-IR patients

SELECT-COMPARE: Pain Reduction SELECT-COMPARE: Pain Reduction SELECT-COMPARE: Pain Reduction
SELECT-COMPARE: Chart legend

Treatment groups are by initial randomization (ANCOVA). Observations after rescue treatment switch were imputed as LOCF.

P≤0.001 for RINVOQ + MTX vs Placebo + MTX; Analysis was not controlled for multiplicity;
P-value obtained through nominal statistical testing.

Please see HUMIRA full Prescribing Information.

Please see HUMIRA full Prescribing Information.

SELECT‑COMPARE

Watch as Dr. Roy Fleischmann discusses RINVOQ efficacy and safety information from the SELECT‑COMPARE study.

SELECT-COMPARE Study Design

Video 1/4

Background information on the robust Phase 3 clinical trial program for RINVOQ and study details for SELECT‑COMPARE.

SELECT-COMPARE Results

Video 2/4

A look at the results of the SELECT‑COMPARE study.

SELECT-COMPARE Safety Data

Video 3/4

An overview of the SELECT‑COMPARE study safety data.

SELECT-COMPARE Highlights

Video 4/4

A summary of the SELECT‑COMPARE trial and important safety information.

RINVOQ + csDMARDs
vs a T‑Cell Inhibitor + csDMARDs

Demonstrated superiority in pain reduction at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in pain reduction at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in pain reduction at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX

SELECT-CHOICE: DAS28-CRP <2.6*

A study in bDMARD-IR patients

SELECT-CHOICE:

DAS28-CRP<2.6*

A study in bDMARD-IR patients

13
30
SELECT-COMPARE: Pain Reduction SELECT-COMPARE: Pain Reduction SELECT-COMPARE: Pain Reduction

*Does not mean drug-free remission or complete absence of disease activity.

Treatment groups are by initial randomization (CMH) and missing data handling by NRI.

*Does not mean drug-free remission or complete absence of disease activity.

RINVOQ SAFETY DATA

Review the well-studied safety profile of RINVOQ,
including both short- and long-term analyses

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking